GlaxoSmithKline (CAI:BIOC) Other Current Liabilities: E£140 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is GlaxoSmithKline Other Current Liabilities?

GlaxoSmithKline CAI:BIOC +20.00% Other Current Liabilities is E£140 Mil as of Sep. 2016.

GlaxoSmithKline's other current liabilities for the quarter that ended in Sep. 2016 was E£140 Mil.

GlaxoSmithKline's quarterly other current liabilities increased from Mar. 2016 (E£135 Mil) to Jun. 2016 (E£158 Mil) but then declined from Jun. 2016 (E£158 Mil) to Sep. 2016 (E£140 Mil).

GlaxoSmithKline's annual other current liabilities increased from Dec. 2013 (E£84 Mil) to Dec. 2014 (E£119 Mil) and increased from Dec. 2014 (E£119 Mil) to Dec. 2015 (E£146 Mil).

GlaxoSmithKline Other Current Liabilities Related Terms

GlaxoSmithKline Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Other Current Liabilities Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Other Current Liabilities
38.35 84.30 119.28 145.65

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.08 145.65 134.88 157.87 139.92

GlaxoSmithKline Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of E£140 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Other Current Liabilities of E£140 Mil as of Sep. 2016. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GlaxoSmithKline.
Is GlaxoSmithKline's Other Current Liabilities too high?
GlaxoSmithKline's current Other Current Liabilities is E£140 Mil.
How does GlaxoSmithKline's Other Current Liabilities compare to PRPH?
GlaxoSmithKline's Other Current Liabilities of E£140 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on GlaxoSmithKline. GlaxoSmithKline's current Other Current Liabilities is E£140 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Other Current Liabilities of E£140 Mil. The current Other Current Liabilities is E£140 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Other Current Liabilities is E£140 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.